[
  {
    "ts": null,
    "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
    "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733775300,
      "headline": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
      "id": 131879613,
      "image": "https://media.zenfs.com/en/zacks.com/00f1f0c06254fc058ca373b7d8f260e5",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
      "url": "https://finnhub.io/api/news?id=09fff222caed8ca9822231b9c36870ad1aab37e77fe8976c65f39e541e4ab1c4"
    }
  },
  {
    "ts": null,
    "headline": "Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma",
    "summary": "AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).",
    "url": "https://finnhub.io/api/news?id=c4d659962fa224197743418475b884e6db96ee9edd8e77873c7b009b3a4789d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733763600,
      "headline": "Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma",
      "id": 131872009,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).",
      "url": "https://finnhub.io/api/news?id=c4d659962fa224197743418475b884e6db96ee9edd8e77873c7b009b3a4789d5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=9a2703eb5e23772a3fa22afc6e7fc5ef464da8d309c9f3372c39267a075f8cee",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762100,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 131933394,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=9a2703eb5e23772a3fa22afc6e7fc5ef464da8d309c9f3372c39267a075f8cee"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study",
    "summary": "On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea",
    "url": "https://finnhub.io/api/news?id=9cab0f0acabc4273d3db1cce9e0e98f895bc99613e59cac8976fd1e477f72c03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733760999,
      "headline": "AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study",
      "id": 131872010,
      "image": "https://media.zenfs.com/en/Benzinga/90b206254cf702c09e45bd1f584ea8a7",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea",
      "url": "https://finnhub.io/api/news?id=9cab0f0acabc4273d3db1cce9e0e98f895bc99613e59cac8976fd1e477f72c03"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.",
    "url": "https://finnhub.io/api/news?id=2976c14d208d85574f90d79d1901566c20898e1a10246239fdce1e46990501b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733749200,
      "headline": "AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease",
      "id": 131872011,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.",
      "url": "https://finnhub.io/api/news?id=2976c14d208d85574f90d79d1901566c20898e1a10246239fdce1e46990501b4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025",
    "summary": "AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025",
    "url": "https://finnhub.io/api/news?id=1c3e6a8a8f3ccfc23aaf7d79cfe1e7f58d20267b7ac2e8df876130ee20fe3bbf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733741520,
      "headline": "AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025",
      "id": 131874384,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025",
      "url": "https://finnhub.io/api/news?id=1c3e6a8a8f3ccfc23aaf7d79cfe1e7f58d20267b7ac2e8df876130ee20fe3bbf"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update",
    "summary": "By Colin Kellaher AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon...",
    "url": "https://finnhub.io/api/news?id=c79f02236f31ed764e67934f5b5a31076c8b5caee4c82dc28168660ed043fa5e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733739864,
      "headline": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update",
      "id": 131869999,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon...",
      "url": "https://finnhub.io/api/news?id=c79f02236f31ed764e67934f5b5a31076c8b5caee4c82dc28168660ed043fa5e"
    }
  },
  {
    "ts": null,
    "headline": "Correction to AbbVie Tavapadon Phase 3 Study Article",
    "summary": "AbbVie said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie's Tavapadon Hits Key Goals in Second Phase 3...",
    "url": "https://finnhub.io/api/news?id=cfe9f3f548d686fef2930785cb7cc3f58e4d6644b6c1dd20ff9ceeb8f904c33f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733738951,
      "headline": "Correction to AbbVie Tavapadon Phase 3 Study Article",
      "id": 131869868,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie's Tavapadon Hits Key Goals in Second Phase 3...",
      "url": "https://finnhub.io/api/news?id=cfe9f3f548d686fef2930785cb7cc3f58e4d6644b6c1dd20ff9ceeb8f904c33f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study",
    "summary": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study",
    "url": "https://finnhub.io/api/news?id=7702baa799134e988f8e25668a99d94bdecab6f790a80fefd59820048e63ee13",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733737980,
      "headline": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study",
      "id": 131874386,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study",
      "url": "https://finnhub.io/api/news?id=7702baa799134e988f8e25668a99d94bdecab6f790a80fefd59820048e63ee13"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie - Investigational Epcoritamab Combination Therapy Shows High Response Rates in Clinical Trial of Patients with Relapsed or Refractory Follicular Lymphoma",
    "summary": "NORTH CHICAGO - AbbVie today announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody...",
    "url": "https://finnhub.io/api/news?id=e252d09caf91300a50a7423d915ce0d6ccef8b6037a4f5eff338afefabf8584d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733736376,
      "headline": "AbbVie - Investigational Epcoritamab Combination Therapy Shows High Response Rates in Clinical Trial of Patients with Relapsed or Refractory Follicular Lymphoma",
      "id": 131869373,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO - AbbVie today announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody...",
      "url": "https://finnhub.io/api/news?id=e252d09caf91300a50a7423d915ce0d6ccef8b6037a4f5eff338afefabf8584d"
    }
  },
  {
    "ts": null,
    "headline": "Don't Miss The Dividend Train: 2 Top Buys To End 2024",
    "summary": "The Dividend Train concept emphasizes the importance of timing when buying dividend stocks. Read more to see my top picks to end 2024.",
    "url": "https://finnhub.io/api/news?id=4913fdd5bae6e26355861c28229c8a85a9fdb91bcecec2b32950bc9dc65dbdf7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733735080,
      "headline": "Don't Miss The Dividend Train: 2 Top Buys To End 2024",
      "id": 131869197,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334957523/image_1334957523.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Dividend Train concept emphasizes the importance of timing when buying dividend stocks. Read more to see my top picks to end 2024.",
      "url": "https://finnhub.io/api/news?id=4913fdd5bae6e26355861c28229c8a85a9fdb91bcecec2b32950bc9dc65dbdf7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Tavapadon Hits Key Goals in Second Phase 3 Parkinson's Study",
    "summary": "By Colin Kellaher AbbVie on Monday said a second late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said...",
    "url": "https://finnhub.io/api/news?id=48aa9354699d014fb66b9fc7eaba5d3644aac2422067001cb831845211cb0632",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733732170,
      "headline": "AbbVie's Tavapadon Hits Key Goals in Second Phase 3 Parkinson's Study",
      "id": 131868615,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie on Monday said a second late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said...",
      "url": "https://finnhub.io/api/news?id=48aa9354699d014fb66b9fc7eaba5d3644aac2422067001cb831845211cb0632"
    }
  },
  {
    "ts": null,
    "headline": "Endometriosis drug research, long underfunded, confronts familiar problems in women’s health",
    "summary": "Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.",
    "url": "https://finnhub.io/api/news?id=d574c9db99690bfa974f2c670d86e439e56fdef5477993579ed40bfbc2315044",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733731200,
      "headline": "Endometriosis drug research, long underfunded, confronts familiar problems in women’s health",
      "id": 131872012,
      "image": "https://imgproxy.divecdn.com/mzQLDEEdEdjcaPbo-tvZzcJM2ZiQm_EW09yaX9YmKsY/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg2NjEwNzY0LmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.",
      "url": "https://finnhub.io/api/news?id=d574c9db99690bfa974f2c670d86e439e56fdef5477993579ed40bfbc2315044"
    }
  }
]